Pfizer shares fall as Covid-19 vaccine and antiviral tablet forecasts miss estimates
However, the company's fourth-quarter results were mixed, with earnings meeting expectations but revenue falling short
By Ishika Dangayach
Published - Feb 08, 2022, 02:35 PM ET
Last Updated - Feb 15, 2024, 07:11 AM EST
• Pfizer's vaccine reports $12.5 billion in sales in the last three months of 2021
• The company anticipates sales of $98 billion to $102 billion in 2022
• The company’s fourth-quarter revenue more than doubled year on year to $23.84 billion
Pfizer Inc. (NYSE: PFE) shares fell 3.78% in premarket trade Tuesday after the drugmaker full-year sales projection for its Covid-19 vaccine and antiviral tablet fell short of analyst expectations.
